=== PAGE 4 ===

COMPLETE PAGE ANALYSIS:
--------------------------------------------------
Nada Glavan
Eisai Inc.
NDA 202834 MA 352; NDA 208277 MA 78                                                                          Page 4

        The violations discussed in this letter do not necessarily constitute an exhaustive list. It is
        your responsibility to ensure that your promotional materials for Fycompa comply with each
        applicable requirement of the FD&C Act and FDA implementing regulations.


                                                                          Sincerely,

                                                                          {See appended electronic signature page}

                                                                          Dhara Shah, PharmD, RAC
                                                                          Regulatory Review Officer
                                                                          Division of Advertising & Promotion Review 1
                                                                          Office of Prescription Drug Promotion

                                                                          {See appended electronic signature page}

                                                                          Aline Moukhtara, RN, MPH
                                                                          Acting Team Leader
                                                                          Division of Advertising & Promotion Review 1
                                                                          Office of Prescription Drug Promotion
Reference ID: 4333421
